Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Elevates Office of Strategic Partnerships and Technology Innovation to Super Office

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The CDRH Office of Strategic Partnerships and Technology Innovation (OST) has been elevated to a super office, effective immediately, a designation that the FDA says will allow OST to adapt…

Continue ReadingFDA Elevates Office of Strategic Partnerships and Technology Innovation to Super Office

FDA Expands In-Person Face-to-Face Meetings for PDUFA, BsUFA, OMUFA

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has expanded its use of in-person face-to-face (FTF) meetings for additional application types, and have expanded its definition of FTF meetings to include hybrid meetings which combine in-person…

Continue ReadingFDA Expands In-Person Face-to-Face Meetings for PDUFA, BsUFA, OMUFA

Legislative Update — Week of Jan. 29, 2024

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Oct. 1, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of Jan. 29, 2024

Quick Notes: European Edition — Jan. 29, 2024

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

In this edition of Quick Notes, we hop across the pond to check out the EMA’s new regulatory fees structure, its updated submissions communication portal, and the sixth update of…

Continue ReadingQuick Notes: European Edition — Jan. 29, 2024

Gene Therapies Require Strong Preclinical Testing, New Guidances Say

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Strong nonclinical testing should underpin development programs for both gene editing (GE) products and chimeric antigen receptor (CAR-T) cellular products, according to two new final guidances issued by the FDA.…

Continue ReadingGene Therapies Require Strong Preclinical Testing, New Guidances Say

FDA Creates “Tiger Team” to Address Efforts to Reduce Use of EtO in Sterilization

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

During its second town hall on reducing the use of ethylene oxide (EtO) to sterilize medical devices, FDA officials announced the creation of a dedicated EtO “tiger team” with expertise…

Continue ReadingFDA Creates “Tiger Team” to Address Efforts to Reduce Use of EtO in Sterilization

U.S. Helium Supply Sale Catches Industry Off-Guard, Prompts Fears of Shortage

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

In a move that caught many industry experts unaware, the U.S. government last week announced the sale of the Federal Helium Reserve to a private company, despite warnings about the…

Continue ReadingU.S. Helium Supply Sale Catches Industry Off-Guard, Prompts Fears of Shortage

Final Guidance Advises on Amendments to Tentatively Approved ANDAs

  • Post author:PacConAdmin
  • Post published:January 26, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Manufacturers with tentatively approved ANDAs can look to a recently issued FDA final guidance for information on how to prepare and submit amendments as well as make requests to get…

Continue ReadingFinal Guidance Advises on Amendments to Tentatively Approved ANDAs

FDA Clarifies Remote Regulatory Assessments in Revised Q&A Guidance

  • Post author:PacConAdmin
  • Post published:January 26, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has revised a previous draft on its current approach to conducting remote regulatory assessments (RRA), incorporating public comments as well as recent amendments to the Food, Drug and…

Continue ReadingFDA Clarifies Remote Regulatory Assessments in Revised Q&A Guidance

Apotex, Two Other Generics Makers Settle for Combined $45M in Price-Fixing Case

  • Post author:PacConAdmin
  • Post published:January 26, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Generic drugmakers Apotex, Heritage and Breckenridge have agreed to settle for a combined $45 million over allegations that they colluded to fix prices. Source: Drug Industry Daily

Continue ReadingApotex, Two Other Generics Makers Settle for Combined $45M in Price-Fixing Case
  • Go to the previous page
  • 1
  • …
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.